Document:

<PAGE>

                                                                    EXHIBIT 10.8

                            STRAIN ACCESS AGREEMENT

     This Strain Access Agreement (the "Agreement"), effective as of December
21, 2000 (the "Effective Date"), is made by and between Maxygen, Inc., a
Delaware corporation ("Maxygen"), and AgraQuest, Inc., a Delaware corporation
("AgraQuest"). Maxygen shall mean Maxygen and its Affiliates.

                                  BACKGROUND

A.   AgraQuest has an extensive collection of organisms in its biodiversity
     collection ("Collection") and is willing to provide access to Maxygen, on a
     non-exclusive basis to at least three thousand (3,000) strains of organisms
     in the Collection.

B.   Maxygen wishes to obtain samples of strains in the Collection in order to
     utilize the strains and material derived from the strains for its benefit.

     Now Therefore, for and in consideration of the covenants, conditions and
undertakings set forth, it is agreed by and between the parties as follows:

1.   DEFINITIONS

     1.1  "Affiliate" means any corporation, firm, limited liability company,
partnership or other entity that directly or indirectly controls or is
controlled by or is under common control with another person.

     1.2  "Biopesticide" means a product intended for use as a Pesticide that
(i) contains a microorganism as the active component or (ii) consists of an
extract from a microorganism as the active component that contains a naturally
occurring substance that controls pests by non-toxic mechanisms.  For the
purposes of this definition, "Biopesticide" shall not include any pesticidal
substance that a plant or plant cells produce from genetic material that has
been introduced into the plant or plant cells (nor shall it include such plant
or plant cells).

     1.3  "Collection Strain" means a strain of organism found in the
Collection.

     1.4  "Confidential Information" means any (i) proprietary or confidential
information or material in tangible form disclosed by one party to the other
hereunder that is marked as "Confidential" at the time it is delivered to the
receiving party, or (ii) proprietary or confidential information disclosed
orally hereunder that is identified as confidential or proprietary when
disclosed and confirmed in writing as confidential within [***] days after such
oral disclosure.

     1.5  "Derived Material" means any material, genetic or otherwise, obtained
from any Selected Strain and any derivatives or modifications made by or for
Maxygen or any of its sublicensees from any Selected Strain or material obtained
therefrom.

     1.6  "Liability" means any liabilities, damages, settlements, claims,
penalties, fines, and reasonable costs or reasonable expenses (including,
without limitation, reasonable attorneys' fees and other expenses of
litigation).

     1.7  "Pesticide" is as defined in the Federal Insecticide, Fungicide and
Rodenticide Act (Section 136(u) of Title 7, Chapter 6 of the United States
Code).

     1.8  "Selected Strain" means a Collection Strain selected by Maxygen to be
received from AgraQuest pursuant to this Agreement.

                                       1

[***] Confidential information has been omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R. Section 230.406.

<PAGE>

     1.9  "Shuffling" means the recombination and/or rearrangement and/or
mutation of genetic material for the creation of genetic diversity using
intellectual property and/or tangible property owned or controlled by Maxygen.

     1.10 "Strain Information" means all information on a Collection Strain,
including, without limitation, taxonomic information, information regarding
biological and/or biochemical activities and any information concerning
intellectual property rights relating to the strain, including rights owned or
controlled by AgraQuest and any rights of third parties.  Strain Information
will include, without limitation, information sufficient for Maxygen to be able
to identify strains of interest for its various research projects.  Strain
Information will also include, without limitation, information identifying the
source of the strain, including the country of original collection and the date
of collection.

2.   ACCESS TO STRAINS

     2.1  Samples.

          2.1.1     Sample Size. Maxygen will have the right to select which
Collection Strains it is to receive from AgraQuest. AgraQuest will supply
Maxygen with samples of at least three thousand (3,000) different Collection
Strains.

          2.1.2     Timing/Rate of Delivery. AgraQuest will deliver to Maxygen
the Selected Strains within thirty (30) days after delivery of notice to
AgraQuest of which Collection Strains Maxygen chooses to receive. It is
anticipated that concurrently with the execution of this Agreement, Maxygen will
notify AgraQuest of (i) up to [***] Collection Strains Maxygen chooses to
receive within thirty (30) days of the Effective Date and (ii) an additional
[***] Collection Strains Maxygen chooses to receive within sixty (60) days of
the Effective Date. Thereafter, Maxygen will notify AgraQuest of an additional
[***] to [***] Collection Strains per month that Maxygen chooses to receive.

          2.1.3     Preparation of Samples. Each Selected Strain provided to
Maxygen by AgraQuest pursuant to this Agreement will be provided as follows:
Each Selected Strain will be delivered as glycerol stocks in 2 ml vials. The
vials will be delivered frozen. Shipments of samples of Selected Strains will be
provided in sample boxes shipped in dry ice. Shipments shall be packaged so as
to arrive at Maxygen with the samples still frozen. [***].

     2.2  Information

          2.2.1     Delivery of Information. Prior to the Effective Date, or as
soon as practicable thereafter, AgraQuest will provide to Maxygen all Strain
Information within its possession or control concerning each Collection Strain
currently in the Collection.

          2.2.2     Future Information. AgraQuest will provide Maxygen with
Strain Information concerning any future strain isolated by AgraQuest, or
otherwise added to the Collection, until Maxygen has selected three thousand
(3,000) strains of organisms from the Collection. Strain Information on newly
isolated strains shall be provided to Maxygen as soon as practicable after being
obtained.

     2.3  Exploitation. Subject to Section 4.3, Maxygen will have the right to
exploit each of the Selected Strains and/or Derived Material in any manner that
Maxygen deems appropriate.

3.   OWNERSHIP AND RIGHTS IN THE SELECTED STRAINS.

                                       2

[***] Confidential information has been omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R. Section 230.406.

<PAGE>

     3.1  Independent Development. AgraQuest retains the right to continue
independent development and investigation of any Selected Strain for which it
may provide a sample to Maxygen. [***].

     3.2  Maxygen Ownership.  Subject to Section 4.3, by virtue of Maxygen's
receipt of a Selected Strain under this Agreement:

          3.2.1     Derived Material.  [***].

          3.2.2     Intellectual Property. Maxygen shall own all rights to and
interest in any idea, invention (whether patentable or not), discovery or
improvement made by or for Maxygen and/or its sublicensees and related to the
Selected Strains or Derived Material, and any uses of the Selected Strains or
Derived Material obtained through use of the Selected Strains or Derived
Material by or for Maxygen and/or its sublicensees, and Maxygen and/or its
sublicensees shall be free to use any such idea, invention, discovery or
improvement, without further obligation to AgraQuest.

4.   LICENSES.

     4.1  License to Selected Strains. AgraQuest hereby grants Maxygen a
non-exclusive, worldwide [***] license, [***] to propagate and use the Selected
Strains [***]. Maxygen sublicensees will be bound by the terms of the license
granted to Maxygen in this Section 4.1.

     4.2  License to Intellectual Property. AgraQuest hereby grants Maxygen a
non-exclusive, worldwide [***] license [***]. Maxygen sublicensees will be bound
by the terms of the license granted to Maxygen in this Section 4.2.

     4.3  AgraQuest Retained Rights. It is understood and agreed that the
licenses granted to Maxygen and any of its sublicensees in Sections 4.1 and 4.2
shall not include the right of Maxygen or its sublicensees to use any Selected
Strain (with or without modification) as a Biopesticide. AgraQuest also retains
(i) the right to use the Selected Strains for any purpose and (ii) its
intellectual property rights relating to the Selected Strains.

     4.4  No License of Maxygen Property. No rights or licenses with respect to
any intellectual property owned by Maxygen or its Affiliates are granted or will
be deemed granted to AgraQuest under this Agreement.

5.   PAYMENTS TO AGRAQUEST

     5.1  Collection Access Fee. Maxygen will pay to AgraQuest a one-time
Collection access fee of [***] within ten (10) business days of the Effective
Date.

     5.2  Milestones.

          5.2.1     Commercial Development. Maxygen will pay to AgraQuest a
milestone payment of [***] upon the commencement of commercial development by
Maxygen or any of its sublicensees of each of its products that contain a gene
isolated from a Selected Strain; provided, however, that milestone payments
pursuant to this Section 5.2.1 shall [***].  The commencement of commercial
development shall occur upon (i) for agricultural products, production of
T2 transgenic seeds of the applicable product or (ii) for chemical products,
production in a 200-liter fermenter of the applicable product.

          5.2.2     Commercial Sale. Maxygen will pay to AgraQuest a milestone
payment of [***] upon the first commercial sale by Maxygen or any of its
sublicensees of each of its products that contain a gene isolated from a
Selected Strain; provided, however, that milestone payments pursuant to this
Section 5.2.2 shall [***].

          5.2.3     Gene Isolated from a Collection Strain. For the purposes of
this Section 5.2, a "gene isolated from a Collection Strain" means an unmodified
gene isolated from a Selected Strain (or a fragment thereof) or a modified form
of a gene isolated from a Selected Strain (or a fragment thereof); provided,
however, in each case that such gene or fragment thereof provides or allows an
activity that cannot be obtained without such gene or fragment.

     5.3  Reports and Payments

                                       3

[***] Confidential information has been omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R. Section 230.406.
<PAGE>

          5.3.1     Milestone Reports. Maxygen will provide AgraQuest with
reports of the attainment of each milestone described in Section 5.2.1 and
Section 5.2.2 as soon as practicable after such event and in any case within
sixty (60) days of such event.

          5.3.2     Milestone Payment. Concurrently with making the reports
described in Section 5.3.1, Maxygen will pay the amounts due under Section 5.2.1
and Section 5.2.2.

6.   FUTURE NEGOTIATIONS

     If Maxygen elects, on or before the third anniversary of the Effective
Date, to commercialize a protein product (e.g., an enzyme) expressed from a gene
isolated from a Selected Strain as a Biopesticide, then Maxygen will give
written notice to AgraQuest of its intention; provided, however, that Maxygen
shall have no obligation to breach any duty of confidentiality to a third party.
In such event, AgraQuest and Maxygen will negotiate in good faith for a period
of up to ninety (90) days from the date of Maxygen's notice, or such further
period as the parties may agree in writing, to enter into a written agreement
establishing the terms of such commercialization by AgraQuest. If no written
agreement is executed within such time Maxygen will have no further obligation
to AgraQuest with respect thereto.

7.   REPRESENTATIONS

     7.1  Sole Owner. AgraQuest represents and warrants that it is the (i) sole
and exclusive owner of, or (ii) co-owner and exclusive licensee of, each of the
Selected Strains and has the right to provide the Selected Strains and the
Strain Information to Maxygen along with any other rights described herein,
without violating its obligations to third parties.

     7.2  No Payment Obligations. AgraQuest represents and warrants that there
are no, and will not be any, payment or other obligations to third parties that
would result from the use by Maxygen or its sublicensees of any Selected Strains
or Derived Material.

     7.3  Power and Authority. Each party represents and warrants that it has
the legal power, authority and right to enter into this Agreement and to perform
its respective obligations set forth herein.

     7.4  No Conflict. Each party represents and warrants that as of the
Effective Date of this Agreement it is not a party to any agreement or
arrangement with any third party or under any obligation or restriction,
including pursuant to its certificate of incorporation or bylaws, that in any
way limits or conflicts with its ability to fulfill any of its obligations under
this Agreement, and will not enter into any such agreement during the term of
this Agreement.

     7.5  Power to Grant Rights. Each party represents and warrants that it has
the right to grant the other party hereto the rights provided under this
Agreement.

8.   CONFIDENTIALITY.

     8.1  Confidential Information. Except as expressly provided herein, the
parties agree that, for the term of this Agreement and for five (5) years
thereafter, the receiving party shall keep completely confidential and shall not
publish or otherwise disclose and shall not use for any purpose except for the
purposes contemplated by this Agreement any Confidential Information furnished
to it by the disclosing party hereto, except that to the extent that it can be
established by the receiving party by written proof that such Confidential
Information:

          (a)  was already known to the receiving party, other than under an
     obligation of confidentiality, at the time of disclosure;

          (b)  was generally available to the public or otherwise part of the
     public domain at the time of its disclosure to the receiving party;

                                       4

[***] Confidential information has been omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R. Section 230.406.
<PAGE>

          (c)  became generally available to the public or otherwise part of the
     public domain after its disclosure and other than through any act or
     omission of the receiving party in breach of this Agreement;

          (d)  was subsequently lawfully disclosed to the receiving party by a
     person other than a party hereto; or

          (e)  was independently developed by the receiving party without use of
     or reference to Confidential Information.

     8.2  Permitted Use and Disclosures. Each party may disclose Confidential
Information disclosed to it by the other party:

          (a)  to the extent such use or disclosure is reasonably necessary in
     complying with applicable law or regulation or legal process, provided that
     if a party is required to make any such disclosure of the other party's
     Confidential Information, other than pursuant to a confidentiality
     agreement, it will give reasonable advance notice to the latter party of
     such disclosure and, will use reasonable efforts to secure confidential
     treatment of such information prior to its disclosure; or

          (b)  is necessary in (x) filing or prosecuting patent applications,
     (y) prosecuting or defending litigation, or (z) making a permitted
     sublicense or otherwise exercising license rights expressly granted by the
     other party to it under this Agreement.

     8.3  Public Disclosures. Either party may disclose that an Agreement exists
between them; however, neither party can disclose the terms of this Agreement
without written consent from the other party.

     8.4  Confidential Terms. Notwithstanding Section 8.3, disclosures may be
made to the extent required to advisors so long as the advisors are bound by
confidentiality obligations comparable to the parties hereto.

9.   INDEMNITY.

     9.1  Maxygen Indemnity to AgraQuest. Maxygen shall indemnify, defend and
hold harmless AgraQuest from and against any claims, actions or suits by a third
party resulting in any Liability arising out of or resulting from (i) a breach
of any representation of Maxygen in Section 7 or (ii) Maxygen's use of any
Selected Strain or Derived Material or the development or manufacture, use,
promotion, marketing, sale or other distribution of any product by Maxygen or
its sublicensees including any Selected Strain or Derived Material, except to
the extent such Liability resulted from AgraQuest's negligence or wrongdoing.

     9.2  AgraQuest Indemnity to Maxygen. AgraQuest shall indemnify, defend and
hold harmless Maxygen from and against any claims, actions or suits by a third
party resulting in any Liability arising out of or resulting from (i) a breach
of any representation of AgraQuest in Section 7 or (ii) Maxygen's use of any
Selected Strain or Derived Material or the development or manufacture, use,
promotion, marketing, sale or other distribution of any product by Maxygen or
its sublicensees including any Selected Strain or Derived Material to the extent
such Liability resulted from AgraQuest's negligence or wrongdoing.

10.  TERMINATION.

     10.1 Term. This Agreement shall be effective as of the Effective Date and,
unless otherwise terminated earlier pursuant to the terms of this Section 10,
shall continue in full force and effect until the [***] of the Effective Date.

     10.2 Termination for Cause. Either party may terminate this Agreement in
the event the other party has materially breached or defaulted in the
performance of any of its obligations hereunder, and such default has continued
for sixty (60) days after written notice thereof was provided to the breaching
party by the nonbreaching party.

                                       5

[***] Confidential information has been omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R. Section 230.406.
<PAGE>

Any termination shall become effective at the end of such sixty (60) day period
unless the breaching party has cured any such breach or default prior to the
expiration of such period.

     10.3 Effect of Termination.

          10.3.1    Accrued Rights and Obligations. Termination of this
Agreement for any reason shall not release any party hereto from any liability
that, at the time of such termination, has already accrued to the other party or
that is attributable to a period prior to such termination, nor preclude either
party from pursuing any rights and remedies it may have hereunder or at law or
in equity with respect to any breach of this Agreement.

          10.3.2    Material Breach by Maxygen. If AgraQuest terminates this
Agreement pursuant to Section 10.2, the licenses granted to Maxygen in Sections
4.1 and 4.2 shall terminate and the provisions of Sections 4.3 and 5 shall
survive; provided, however, that if the material breach or default causing the
termination relates only to certain Selected Strains and/or certain products,
the licenses granted to Maxygen in Sections 4.1 and 4.2 shall terminate only in
regard to such Selected Strains and/or products and shall survive as to all
other Selected Strains and products.

          10.3.3    Material Breach by AgraQuest. If Maxygen terminates this
Agreement pursuant to Section 10.2: (i) AgraQuest shall pay to Maxygen an access
termination fee equal to [***] pursuant to Section 2.1.1 and (ii) the provisions
of Sections 4, 5 and 6 shall not survive.

          10.3.4    Other Termination. If this Agreement terminates according to
Section 10.1, the provisions of Sections 2.3, 4 and 5 shall survive the
termination of this Agreement.

          10.3.5    Survival. The provisions of Sections 3, 4.4, 7, 8, 9, 10 and
11 shall survive the expiration or termination of this Agreement for any reason.

11.  MISCELLANEOUS.

     11.1 Governing Law; Venue. This Agreement and any dispute arising from the
performance or breach hereof shall be governed by and construed and enforced in
accordance with the laws of the state of California, without reference to
conflicts of laws principles. The exclusive venue of any dispute arising out of
or in connection with the performance or breach of this Agreement shall be the
California state courts in or U.S. district court for the County of San Mateo,
CA, and the parties hereby consent to the personal jurisdiction of such courts.

     11.2 Assignment; Successors. This Agreement shall not be assignable by
either party to any third party without the written consent of the other party;
except either party may assign this Agreement, without such consent, to (i) an
Affiliate of such party; or (ii) an entity that acquires all or substantially
all of the business or assets of such party, whether by merger, reorganization,
acquisition, sale, or otherwise, which agrees in writing to be bound by the
terms and conditions of this Agreement. The terms and conditions of this
Agreement shall be binding on and inure to the benefit of the permitted
successors and assigns of the parties.

     11.3 Notices. Any notices, requests and other communications hereunder
shall be in writing and shall be personally delivered or sent by international
express delivery service, registered or certified mail, return receipt
requested, postage prepaid, in each case to the respective address specified
below, or such other address as may be specified in writing to the other party
hereto:

          Maxygen:       Maxygen, Inc.
                         515 Galveston Drive
                         Redwood City, CA 94063
                         Attn: General Counsel

          AgraQuest:     AgraQuest, Inc.

                                       6

[***] Confidential information has been omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R. Section 230.406.
<PAGE>

                         1530 Drew Avenue
                         Davis, CA 95616
                         Attn: President

     11.4 Independent Contractors. The relationship of the parties is that of
independent contractors. The parties are not deemed to be agents, partners or
joint venturers of the other for any purpose as a result of this Agreement or
the transactions contemplated hereby.

     11.5 Further Assurances. Each party shall execute and cause to be delivered
to the other party such instruments and other documents, and shall take such
other actions, as such other party may reasonably request in order for the
requesting party to obtain the full benefits of this Agreement and the
transactions contemplated hereby.

     11.6 Compliance with Laws. In exercising their rights under this license,
the parties shall fully comply in all material respects with the requirements of
any and all applicable laws, regulations, rules and orders of any governmental
body having jurisdiction over the exercise of rights under this Agreement.

     11.7 Entire Agreement; Amendment. This Agreement constitutes the entire
agreement, both written and oral, with respect to the subject matter hereof, and
supersedes all prior or contemporaneous understandings or agreements, whether
written or oral, with respect to such subject matter. This Agreement may only be
amended in a writing signed by both parties.

     11.8 Headings. The captions to the Sections are not a part of this
Agreement, but are included merely for convenience of reference and shall not
affect its meaning or interpretation.

     11.9 Counterparts. This Agreement may be executed in two counterparts, each
of which shall be deemed an original and which together shall constitute one
instrument.

     In Witness Whereof, the parties have executed and delivered this Agreement
as of the date first above written.

Maxygen, Inc.                           AgraQuest, Inc.

By:/s/ John R. Bedbrook                   By: /s/ Pamela G. Marrone
   --------------------                       ----------------------
   Name:John R. Bedbrook                      Name: Pamela G. Marrone
   Title: President of Agriculture            Title: President & CEO

                                       7

[***] Confidential information has been omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R. Section 230.406.<PAGE>

                                AGRAQUEST, INC.

                                      AND

                          DRAGOCO GERBERDING & CO. AG

                               LICENSE AGREEMENT

     Certain confidential information contained throughout this document, marked
     by "[***]" has been omitted and filed with the Securities and Exchange
     Commission pursuant to 17 C.F.R (S) 230.406, General Rules and Regulations,
     Securities Act of 1933.
<PAGE>

                               LICENSE AGREEMENT

     THIS LICENSE AGREEMENT, including the exhibits referred to herein and
attached hereto (the "Agreement"), effective as of July 1, 2001 (the "Effective
Date"), is made and entered into by and between AgraQuest, Inc., a Delaware
corporation having a principal place of business located at 1530 Drew Avenue,
Davis, California 95616 ("AgraQuest") and Dragoco Gerberding & Co. AG having a
principal place of business located at Dragocostrasse, D 36703 Holzminnden,
Germany ("Licensee").

                                   RECITALS

     A.  WHEREAS AgraQuest owns or has the right to grant licenses under certain
patents, patent applications, technology, trade secrets, data, know-how and
other intellectual property relating to [***] insect repellant and any
derivatives, analogs, or combinations with other repellant materials; and

     B.  WHEREAS Licensee desires to obtain from AgraQuest, and AgraQuest is
willing to grant to Licensee, a license under such technology and intellectual
property for the development and commercialization of certain products and
services under the terms and conditions herein.

     NOW, THEREFORE, in consideration of the mutual covenants and obligations
set forth herein, and for other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, AgraQuest and Licensee hereby agree
as follows:

1.   DEFINITIONS

     As used in this Agreement, the following terms shall have the meanings
indicated:

     1.1.    "Confidential Information" shall have the meaning set forth in
Section 10.1 below.

     1.2.    "Deductible Expenses" "shall mean the following items of expense
actually incurred in connection with Sales of Licensed Products to the extent
paid or allowed by Licensee or Sublicensees and included in accordance with
recognized principles of accounting (consistently applied) in the gross sales
price billed: (a) sales, use or turnover taxes; (b) excise, value added or other
taxes, custom duties or consular fees; (c) transportation, freight, and handling
charges, and insurance on shipments to customers; (d) trade, cash or quantity
discounts or rebates to the extent actually granted; (e) agent fees or
commissions; and (f) refunds and credits for any rejected or returned Licensed
Products or because of retroactive price reductions, rebates or chargebacks.

     1.3.    "Field" shall mean the manufacture, use and sale of insect
repellents in toiletries and cosmetics.

     1.4.    "Improvements" shall mean the improvements, modifications, or
enhancements to the Licensed Patents.

     1.5.    "Joint Inventions" means inventions made or conceived jointly by or
for employees of AgraQuest and Licensee during the term of this Agreement and
which, under principles arising under the patent laws and regulations of the
United States governing inventorship, would be found to be jointly

[***] Confidential information has beem omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R (S) 230.406.

                                       1
<PAGE>

invented by AgraQuest and Licensee, and all intellectual property and
proprietary rights therein, thereto and thereunder.

     1.6.    "Licensed Patents" shall mean those patents, inventors'
certificates and patent applications set forth in Exhibit A, together with any
renewal, division, continuation, continued prosecution application or
continuation-in-part of any of such patents, certificates and applications, any
and all patents or certificates of invention issuing thereon, and any and all
reissues, reexaminations, extensions, divisions, renewals of or to any of the
foregoing, and any foreign counterparts of any of the foregoing.

     1.7.    "Licensed Product" shall mean any material, composition, product,
device, or procedure the manufacture, use or sale of which would infringe a
Valid Claim in the country of such manufacture, use or sale, but for a license
granted hereunder.

     1.8.    "Net Revenues" shall mean the combined amounts (whether in cash or
in non-cash consideration) received or invoiced by Licensee and Sublicensees,
whichever is earlier, from Sales of Licensed Products to third parties, less
Deductible Expenses.

     1.9.    "Sale" or "Sold" shall mean the sale, transfer, exchange or other
disposition of Licensed Products by or for Licensee of a Sublicensee whether by
gift or otherwise, including but not by way of limitation, the use of Licensed
Products.  Any commercial use of a Licensed Product by Licensee or a Sublicensee
shall be considered a Sale hereunder for accounting and royalty purposes.  Sales
of Licensed Products shall be deemed consummated upon the first to occur of:

             (a)  receipt of payment from the purchaser;

             (b)  delivery of Licensed Products to the purchaser or a common
carrier at the risk of the purchaser;

             (c)  release of Licensed Products from consignment;

             (d)  if deemed sold by use, when first put to such use; or

             (e)  if otherwise transferred, exchanged or disposed of whether by
gift or otherwise when such transfer, exchange, gift or other disposition occurs

     1.10.   "Sublicensee(s)" shall mean any third party to whom Licensee has
sublicensed any or all of the rights in, to and under the Licensed Patents
licensed to Licensee hereunder.

     1.11.   "Sublicense Income" shall mean any proceeds, whether cash or non-
cash consideration, received by Licensee in connection with a grant of a
sublicense to the Licensed Patents, including without limitation any license fee
payments, milestone payments, royalty payments or other cash revenues related to
such sublicense grant. For the avoidance of doubt, Sublicense Income does not
include amounts received by Sublicensee for Sales of Licensed Products, which
shall constitute Net Revenues. In addition, Sublicense Income shall not include
amounts received (a) in consideration of equity or dept securities of Licensee
(with the exception of equity premiums) or (b) in consideration for the license
or sublicense of any intellectual property other than Licensed Patents.

[***] Confidential information has beem omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R (S) 230.406.

                                       2
<PAGE>

     1.12.  "Valid Claim" shall mean (a) any claim of an issued and unexpired
patent within the Licensed Patents which has not been held unenforceable or
invalid by a court or other governmental agency of competent jurisdiction in an
unappealed or unappealable decision, and which has not been disclaimed or
admitted to be invalid or unenforceable through reissue or otherwise, or (b) a
claim in a pending patent application within the Licensed Patents.

2.   LICENSES

     2.1.   License Grant. Subject to the terms and conditions of this
Agreement, AgraQuest hereby grants to Licensee a [***], royalty bearing,
exclusive license, including the right to grant sublicenses in accordance with
Section 2.3, under the Licensed Patents to [***] (and to have such rights
exercised on Licensee's behalf by third parties).

     2.2.   Ownership; Reservation of Rights. Licensee acknowledges and agrees
that AgraQuest shall retain ownership of the Licensed Patents, and the
Improvements, subject only to the rights and licenses expressly granted herein.
Except as expressly provided herein, no right, title, or interest is granted by
AgraQuest to Licensee, implied or otherwise, in to or under the Licensed
Patents, or the Improvements.

     2.3.   Sublicenses.  Subject to the terms and conditions of this Agreement,
Licensee shall have the right to sublicense any or all of the rights granted to
Licensee under Section 2.1; provided that any such sublicense (a) shall be made
pursuant to a binding and written agreement which protects AgraQuest's interests
and rights in its proprietary information and intellectual property to at least
the same extent as this Agreement, (b) shall contain provisions for the benefit
of AgraQuest substantially similar in language and scope to Articles 4, 5, 8, 9,
10, and 11, and Sections 2.3, 3.3, 7.3 of this Agreement and (c) shall be of no
greater scope than the license granted to Licensee in Section 2.1.  Licensee
shall provide AgraQuest with a copy of each fully executed sublicense agreement
in which Licensee sublicenses any or all of the rights set forth in Section 2.1
which Licensee may enter into during the term of this Agreement.

3.   PAYMENTS AND RELATED OBLIGATIONS

     3.1.   Royalty Payments. In consideration for the rights and licenses
granted pursuant to Article 2 above, Licensee shall make royalty payments to
AgraQuest as follows:

            3.1.1.  Licensee shall pay to AgraQuest each calendar quarter
running royalties in the amount of [***].

            3.1.2.  Licensee shall pay to AgraQuest each calendar quarter
running royalties in the amount of [***].

            3.1.3.  [***] shall be due or payable because the manufacture, use,
offer for sale, sale or import of any Licensed Product is or shall be covered by
more than one Valid Claim.

     3.2.   Royalty Term. Licensee's obligation to pay royalties to AgraQuest
under Section 3.1 shall continue on a Licensed Product by Licensed Product,
country by country basis, until the expiration or final determination of
invalidity of the last Valid Claim within the Licensed Patents. Notwithstanding
the above, Licensee shall be obligated after expiration of the royalty term to
pay any royalty amounts that accrued under Section 3.1 prior to such expiration.
Licensee acknowledges and agrees that Licensee shall

[***] Confidential information has beem omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R (S) 230.406.

                                       3
<PAGE>

be solely responsible for paying all royalties owed to AgraQuest on account of
Net Revenues and Sublicensee Income by any and all Sublicensees.

     3.3.   Royalty Reports. Licensee shall deliver to AgraQuest, within [***]
days after the end of each calendar quarter in which Licensed Products are Sold,
a written report setting forth in reasonable detail (a) the calculation of the
royalties payable to AgraQuest for such calendar quarter under Section 3.1,
including the number and types of Licensed Products Sold and distributed in each
country, gross sales, Net Revenues thereof and Deductible Expenses, and (b) all
Sublicensee Income received on a Sublicensee by Sublicensee basis and further
organized based on the type of payment (e.g., royalty, license fee, milestone).

     3.4.   Payment Terms.

            3.4.1.  Licensee shall pay all royalties due and payable on [***]
pursuant to Section 3.1.1 within [***] days after the last day of each quarter
in which the applicable Licensed Products are Sold by Licensee or Sublicensees.

            3.4.2.  Licensee shall pay all royalties due and payable on
Sublicensee Income pursuant to Section 3.1.2 within [***] days after the last
day of each quarter in which such Sublicense Income is due and payable to
Licensee.

            3.4.3.  Except as otherwise expressly provided herein, all other
payments due to AgraQuest pursuant to the terms and conditions of this Agreement
shall be due and payable within [***] after receipt of a proper invoice therefor
from AgraQuest. Any sums not paid when due, including amounts determined to be
due under Section 3.6, shall automatically accrue interest from the date when
due until actually paid at a rate of [***].

            3.4.4.  All payments made by Licensee under this Agreement shall be
made in United States dollars, and such payments shall be made by check or wire
transfer to one or more bank accounts to be designated in writing by AgraQuest.
In the event that Licensed Products are sold in currencies other than United
States dollars, Net Revenues shall be calculated by Licensee by conversion of
foreign currency to U.S. dollars at the conversion rate existing in the United
States (referencing the "U.S. dollar noon buying rates", or its equivalent,
published in the Wall Street Journal) on the last working day of each period
during which royalties are calculated, net of applicable exchange related
charges, or otherwise in accordance with generally accepted accounting
principles consistently applied.

     3.5.   Taxes.  Licensee shall pay, and shall indemnify and hold AgraQuest
harmless from, all taxes, duties and levies directly imposed by all foreign,
federal, state, local or other taxing authorities (including, without
limitation, export, sales, use, excise, and value-added taxes) based on the
transactions or payments under this Agreement, other than taxes imposed or based
on AgraQuest's net income.  All amounts payable hereunder by Licensee shall be
paid without deduction or withholding for or on account of any present or future
tax, levy, impost, fee, assessment, deduction or charge by any taxing authority.
Notwithstanding the foregoing, if Licensee is required by law to deduct or
withhold any taxes, levies, imposts, fees, assessments, deductions or charges
from or in respect of any amounts payable hereunder to AgraQuest, (a) Licensee
shall pay the relevant taxation authority the minimum amounts necessary to
comply with the applicable law, (b) Licensee shall make such payment prior to
the date on which interest or penalty is attached thereto, and (c) the amounts
payable by Licensee to AgraQuest under this Agreement shall be increased as may
be necessary so that, after Licensee makes all required deductions or

[***] Confidential information has beem omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R (S) 230.406.

                                       4
<PAGE>

withholdings, AgraQuest shall receive amounts equal to the amounts it would have
received had no such deductions or withholdings been required.

     3.6.   Inspection of Books and Records. Licensee shall maintain, and
require its Sublicensees to maintain, complete and accurate books and records
which enable the calculation of royalties and other payments payable hereunder
to be verified. Licensee and its Sublicensees shall retain such books and
records for each quarterly period for ten (10) years after the submission of the
corresponding report under this Section 3.6. Upon two weeks prior notice to
Licensee, AgraQuest or independent accountants selected by AgraQuest may have
access to such books and records to conduct a review or audit no more than twice
per calendar year at AgraQuest's discretion, for the sole purpose of verifying
the accuracy of Licensee's payments, any Sublicensees' payments and Licensee's
compliance with this Agreement. Such access shall be permitted during Licensee's
normal business hours during the term of this Agreement and for three (3) years
after the expiration or termination of this Agreement. In the event of any
underpayment, Licensee shall promptly pay to AgraQuest the difference between
the amount actually paid by Licensee and the amount determined to be owing under
this Section 3.6. Any such inspection or audit shall be at AgraQuest's expense,
unless the inspection or audit results in a determination that Licensee's
payment obligations to AgraQuest have been understated, or that Licensee's
payments have been underpaid, by more than five percent (5%) of the amount
actually paid by Licensee for the period examined, in which case Licensee shall
pay all reasonable costs and expenses incurred by AgraQuest in the course of
making such determination, including the fees and expenses of such accountant.

4.   DUE DILIGENCE

     4.1.   Development Reports. Licensee shall deliver to AgraQuest, within
[***] following the Effective Date, a written report setting forth in reasonable
detail (a) the identity of all Licensed Products or prototype products in
research or manufacturing, (b) the stage of development for each such Licensed
Product or prototype licensed and (c) the partnership or collaboration status,
if any, of Licensee's efforts in connection with such Licensed Products.

     4.2.   Efforts. Licensee agrees to [***] develop and commercialize Licensed
Products and to obtain such approvals as may be necessary for the sale of
Licensed Products in the United States and in other major countries. Licensee
may conduct such activities itself or through third parties. Without limiting
and in addition to the foregoing, to satisfy its diligence obligations under
this Article 4, Licensee must (a) provide written reports to AgraQuest in
accordance with Section 4.1 and (b) upon AgraQuest's written and reasonable
request, demonstrate to AgraQuest's satisfaction that it is proceeding with a
Licensed Product in a manner consistent with moving such. If AgraQuest
determines that Licensee is not making suitable progress towards
commercialization of Licensed Products, AgraQuest shall have the right in its
sole discretion to terminate this Agreement pursuant to Section 9.2.

5.   IMPROVEMENTS AND JOINT INVENTIONS.

     5.1.   Disclosure. As soon as reasonably possible, either upon creation,
development of an Improvement or conception or reduction to practice of a Joint
Invention, as the case may be, each party shall disclose the same in writing to
the other. All such disclosures shall be maintained in confidence by the
receiving party.

     5.2.   Improvements.

[***] Confidential information has beem omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R (S) 230.406.

                                       5
<PAGE>

             5.2.1. In the event that AgraQuest develops or creates
Improvements, and subject to the terms and conditions of this Agreement, [***].

             5.2.2. In the event that Licensee develops or creates Improvements,
and subject to the terms and conditions of this Agreement, Licensee agrees to
grant and hereby grants to AgraQuest a worldwide, royalty-free, sublicensable,
non-cancellable, exclusive right and license, under Licensee's right, title and
interest to and under the Improvements to make, use, sell, distribute, offer to
sell, import and export such Improvements (and to have such rights exercised on
AgraQuest's behalf by third parties) outside the Field.

     5.3.    Patent Prosecution.

             5.3.1. AgraQuest shall have the initial right but not the
obligation to file, prosecute and maintain all patents, patent applications and
inventors' certificates claiming or covering Joint Inventions (the "Joint
Patents"). In the event that AgraQuest elects to file, prosecute and maintain a
Joint Patent, (a) Licensee agrees to assign and hereby assigns to AgraQuest all
of it right, title and interest in and to such Joint Patent and (b) AgraQuest
agrees that such Joint Patent shall be included in the license granted under
Section 2.1 herein. AgraQuest shall add such Joint Patent to Exhibit A attached
hereto. AgraQuest shall provide Licensee with all material documentation and
correspondence from, sent to or filed with patent offices regarding such Joint
Patents and with a reasonable opportunity to review and comment upon all filings
with such patent offices in advance. [***]. All expenses to be paid or
reimbursed by Licensee pursuant to this Section 5.3.1 shall be obligations that
are separate and apart from other payment obligations described in this
Agreement and shall be invoiced and paid separately.

             5.3.2. In the event that AgraQuest elects to not to file, prosecute
and maintain a Joint Patent, or thereafter elects not to continue prosecution of
any such patent application, or elects not to maintain any patent that may issue
therefrom Licensee shall have the right but not the obligation, at Licensee's
option and expense, to file for and prosecute such patent application and
maintain such patent. In such event, (a) AgraQuest agrees to assign and hereby
assigns to AgraQuest all of it right, title and interest in and to such Joint
Patent and (b) Licensee agrees to grant and hereby grants to AgraQuest an
exclusive, royalty-free, non-cancellable, worldwide license in, to and under
Licensee's right, title and interest to such Joint Patent outside the Field, it
being understood that Licensee retains exclusively all rights under such Joint
Patent within the Field. Licensee shall provide AgraQuest with all material
documentation and correspondence from, sent to or filed with patent offices
regarding such Joint Patents and with a reasonable opportunity to review and
comment upon all filings with such patent offices in advance. [***].

     5.4.    Cooperation. Each party will cooperate with the other party to
execute all lawful papers and instruments and to make all rightful oaths and
declarations as may be necessary in the preparation and prosecution of all
patents and other filings referred to in this Article 5.

6.   PATENT MAINTENANCE AND ENFORCEMENT

     6.1.    Patent Enforcement.

             6.1.1.  If either party hereto becomes aware that any Licensed
Patents or Joint Patents are being or have been infringed by any third party in
the Field, such party shall promptly notify the other party hereto in writing
describing the facts relating thereto in reasonable detail. AgraQuest shall have
the

[***] Confidential information has beem omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R (S) 230.406.

                                       6
<PAGE>

initial right, but not the obligation, as to Licensee to institute, prosecute
and control any action, suit or proceeding (an "Action") with respect to such
infringement in the Field, including any declaratory judgment action, at its
expense, using counsel of its choice and Licensee shall cooperate reasonably
with AgraQuest, at AgraQuest's request, in connection with any such Action.
[***].

             6.1.2.  In the event AgraQuest fails to initiate any Action
involving the Licensed Patents or Joint Patents within [***] of receiving notice
of any commercially significant infringement, Licensee shall have the right, but
not the obligation, to initiate and/or maintain such Action at its expense, and
AgraQuest shall cooperate reasonably with Licensee, at Licensee's request, in
connection with any such Action. [***].

             6.1.3. If Licensee initiates and maintains an infringement action
on AgraQuest's behalf pursuant to Section 6.1.2 with respect to the infringement
of any Licensed Patents or Joint Patents, Licensee' reasonable and customary
expenses for such action (including attorneys' fees and expert fees) shall be
[***].

             6.1.4. If Licensee initiates and maintains an infringement action
on AgraQuest's behalf pursuant to Section 6.1.2, and subsequently decides to
abandon such an action other than pursuant to a settlement with the alleged
infringer, Licensee shall give AgraQuest timely notice so that AgraQuest or its
licensor may, at its option and if it so desires, continue such action.

     6.2.    Cooperation. In any Action, the parties shall provide each other
with reasonable cooperation and assistance, including agreeing to be named as a
party to such Action, and, upon the request and at the expense of the party
bringing such Action, the other party shall make available, at reasonable times
and under appropriate conditions, all relevant personnel, records, papers,
information, samples, specimens, and the like in its possession. Notwithstanding
any other provision of this Article 6, neither party shall make any settlements
of any suit, proceeding or action relating to an infringement of any Licensed
Patents in the Field or Joint Patents that would materially and adversely affect
the other party or the rights and licenses granted hereunder without first
obtaining such other party's prior written consent, such consent not to be
unreasonably withheld or delayed.

7.   REPRESENTATIONS, WARRANTIES AND COVENANTS

     7.1.    Representations, Warranties and Covenants of AgraQuest.  AgraQuest
represents and warrants that, as of the Effective Date:

             7.1.1.  AgraQuest is a corporation, duly organized, validly
existing and in good standing under the laws of its state of incorporation;

             7.1.2.  AgraQuest has the right and authority to grant the rights
and licenses granted to Licensee under this Agreement;

             7.1.3.  The execution, delivery and performance of this Agreement
has been duly authorized by all necessary corporate action on the part of
AgraQuest.

     7.2.    Representations, Warranties and Covenants of Licensee.  Licensee
represents, warrants and covenants that, as of the Effective Date:

[***] Confidential information has beem omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R (S) 230.406.

                                       7
<PAGE>

             7.2.1.  Licensee is a corporation, duly organized validly existing
and in good standing under the laws of its state of incorporation;

             7.2.2.  The execution, delivery and performance of this Agreement
has been duly authorized by all necessary corporate action on the part of
Licensee; and

             7.2.3.  Licensee will not practice any of the rights in, to or
under the Licensed Patents or Joint Patents outside of the Field.

     7.3.    Nothing in this Agreement shall be construed as conferring, by
implication, estoppel or otherwise, any license or rights under any patents of
AgraQuest other than the Licensed Patents, regardless of whether such patents
are dominant or subordinate to the Licensed Patents.

     7.4.    Disclaimer. EXCEPT AS EXPRESSLY PROVIDED FOR IN THIS AGREEMENT,
NEITHER PARTY MAKES, AND EACH PARTY HEREBY DISCLAIMS, ANY AND ALL
REPRESENTATIONS AND WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, WITH RESPECT TO
THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING WITHOUT LIMITATION, WARRANTIES
OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT AND
ANY WARRANTY ARISING OUT OF PRIOR COURSE OF DEALING AND USAGE OF TRADE.

8.   INDEMNIFICATION

     8.1.    Indemnity. Licensee shall indemnify, defend and hold harmless
AgraQuest and its directors, officers, employees, agents and consultants (each
an "Indemnitee") from and against any and all liabilities, damages, losses,
costs or expenses (including reasonable attorneys' and professional fees and
other expenses of litigation and/or arbitration) (a "Liability") resulting from
or arising out of a claim, suit or proceeding brought by a third party against
an Indemnitee for personal injury, death, product liability or property damage
arising out of or related to the manufacture, use, or sale of Licensed Products
except to the extent such claim is caused by the gross negligence or willful
misconduct of AgraQuest.

     8.2.    Procedure. For purposes of Section 8.1, the Indemnitee shall give
prompt written notice to Licensee of any claims, suits or proceedings by third
parties which may give rise to any claim for which indemnification may be
required under this Article 8. Licensee shall be entitled to assume the defense
and control of any such claim at its own cost and expense; provided, however,
that the Indemnitee shall have the right to be represented by its own counsel at
its own cost in such matters. Neither Licensee nor the Indemnitee shall settle
or dispose of any such matter in any manner which would adversely affect the
rights or interests of the other party (including the obligation to indemnify
hereunder) without the prior written consent of the other party, which shall not
be unreasonably withheld or delayed. Each party shall reasonably cooperate with
the other party and its counsel in the course of the defense of any such suit,
claim or demand, such cooperation to include without limitation using reasonable
efforts to provide or make available documents, information and witnesses.

9.   TERM AND TERMINATION

     9.1.    Term. The term of this Agreement shall commence on the Effective
Date and continue in full force and effect until expiration or termination of
Licensee' royalty payment obligations as

[***] Confidential information has beem omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R (S) 230.406.

                                       8
<PAGE>

specified under Section 3.1, unless and until terminated at an earlier date in
accordance with Section 9.2 below.

     9.2.    Termination for Cause. If either party materially breaches any term
or condition of this Agreement, including without limitation Sections 4.2 and
7.2 and the failure of Licensee to meet the minimum royalty payment of [***],
the other party may notify the breaching party in writing of such breach,
setting forth the nature of the breach in reasonable detail. [***].

     9.3.    Effect of Termination; Survival. Section 9.3 and Articles 3 (to the
extent provided therein), 7 (to the extent provided therein), 8, 9, 10 and 11
shall survive expiration or termination of this Agreement. [***]. All other
provisions of this Agreement shall be of no further force and effect upon such
expiration or termination of this Agreement. Notwithstanding the foregoing,
expiration or termination of this Agreement shall not release either party from
any obligation that has accrued prior to such expiration or termination,
including without limitation any obligation to pay any amount which became due
and payable under the terms and conditions of this Agreement prior to such
expiration or termination.

10.  CONFIDENTIAL INFORMATION

     10.1.  Confidentiality. In connection with this Agreement, the parties will
provide to each other Confidential Information, including but not limited to
each party's know-how, invention disclosures, proprietary materials and/or
technologies, economic information, business or research strategies, trade
secrets and material embodiments thereof. As used herein, "Confidential
Information" means any information of a confidential or proprietary nature
disclosed by a party to this Agreement to the other party in written or oral
form.

     10.2.  Confidentiality and Non-Use. The recipient of a disclosing party's
Confidential Information shall maintain such Confidential Information in
confidence, and shall disclose such Confidential Information only to those of
its employees, agents, consultants, sublicensees, attorney's, accountants and
advisors who have a reasonable need to know such Confidential Information and
who are bound by obligations of confidentiality and non-use no less restrictive
then those set forth herein. The recipient of the disclosing party's
Confidential Information shall use such Confidential Information solely to
exercise its rights and perform its obligations under this Agreement (including,
without limitation, the right to use and disclose such Confidential Information
in regulatory applications and filings), unless otherwise mutually agreed in
writing. The recipient of the other party's Confidential Information shall take
the same degree of care that it uses to protect its own confidential and
proprietary information of a similar nature and importance (but in any event no
less than reasonable care).

     10.3.  Exclusions. Confidential Information shall not include information
that: (a) is in the recipient's possession prior to receipt from the disclosing
party as demonstrated by contemporaneous documentation; (b) is or becomes,
through no fault of the recipient, publicly known; (c) is furnished to the
recipient by a third party without breach of a duty to the disclosing party; (d)
is independently developed by the recipient without use of, application of or
reference to the disclosing party's Confidential Information as demonstrated by
contemporaneous documentation.

     10.4.  Legal Disclosures. It shall not be a violation of this Article 10 to
disclose Confidential Information required to be disclosed under applicable law,
but such disclosure shall be only for the sole purpose of and solely to the
extent required by such law, and provided that the recipient, to the extent
possible, shall give the disclosing party prior written notice of the proposed
disclosure and cooperate fully

[***] Confidential information has beem omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R (S) 230.406.

                                       9
<PAGE>

with the disclosing party to minimize the scope of any such required disclosure,
to the extent possible and in accordance with applicable law.

     10.5.  Termination.  All obligations of confidentiality and non-use imposed
under this Article 10 shall expire three (3) years after the termination of this
Agreement.

11.  MISCELLANEOUS

     11.1.  Use of Name.  Licensee agrees that it shall not use the name of the
AgraQuest in any advertising or publicity material, or make any form of
representation or statement which would constitute an express or implied
endorsement by AgraQuest of any Licensed Product, and that it shall not
authorize others to do so, without first having obtained written approval from
AgraQuest, except as may be required by governmental law, rule or regulation.

     11.2.  Press Releases.  The parties may agree to issue a joint press
release upon execution of this Agreement or as promptly as practicable
thereafter. The content of any such joint press release will be agreed upon by
both parties.

     11.3.  Marking Requirement.  Licensee agrees to mark the appropriate patent
number or numbers on all Licensed Products made or Sold in accordance with all
applicable governmental laws, rules and regulations to the extent reasonably
possible, and to require its Sublicensees to do the same.

     11.4.  Governing Law.  This Agreement shall be governed by, and construed
and interpreted, in accordance with the internal laws of the State of California
(as permitted by Section 1646.5 of the California Civil Code or any similar
successor provision) without giving effect to any choice of law rule that would
cause the application of the laws of any jurisdiction other than the internal
laws of the State of California to the rights and duties of the parties.

     11.5.  Export Regulations.  Licensee agrees that this Agreement is subject
in all respects to the laws and regulations of the United States of America,
including the Export Administration Act of 1979, as amended, and any regulations
thereunder.

     11.6.  Limitation of Liability.  EXCEPT WITH RESPECT TO EACH PARTY'S
INDEMNITY OBLIGATIONS UNDER ARTICLE 8 AND CONFIDENTIALITY OBLIGATIONS UNDER
ARTICLE 11, IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR INCIDENTAL,
CONSEQUENTIAL, INDIRECT, PUNITIVE OR SPECIAL DAMAGES OF THE OTHER PARTY ARISING
OUT OF OR RELATED TO THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF
LIABILITY EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

     11.7.  Arbitration.  All disputes arising between the parties under this
Agreement will be settled by arbitration conducted in the English language in
accordance with the Commercial Arbitration Rules of the American Arbitration
Association.  The parties will cooperate with each other in causing the
arbitration to be held in as efficient and expeditious a manner as practicable.
Any arbitration proceeding instituted under this Agreement will be brought in a
mutually agreeable neutral territory.  Any award rendered by the arbitrators
will be final and binding upon the parties hereto.  Judgment upon the award may
be entered in any court of record of competent jurisdiction.  Each party will
pay its own expenses of arbitration and the expenses of the arbitrators will be
equally shared unless the arbitrators assess as part of their award all or any
part of the arbitration expenses of one party (including reasonable attorneys'
fees) against the other party.   Each party irrevocably and unconditionally
consents to the jurisdiction of any

[***] Confidential information has beem omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R (S) 230.406.

                                       10
<PAGE>

such proceeding and waives any objection that it may have to personal
jurisdiction or the laying of venue of any such proceeding.

     11.8.  Force Majeure.  Neither party shall be held responsible for any
delay or failure in performance (with the exception of the payment of money)
hereunder to the extent caused by strikes, embargoes, unexpected government
requirements, civil or military authorities, acts of God, earthquake, or by the
public enemy or other causes reasonably beyond such party's control and without
such party's fault or negligence; provided that the affected party notifies the
unaffected party as soon as reasonably possible, and resumes performance
hereunder as soon as reasonably possible following cessation of such force
majeure event.

     11.9.  Independent Contractors.  The relationship of AgraQuest and Licensee
established by this Agreement is that of independent contractors.  Nothing in
this Agreement shall be constructed to create any other relationship between
AgraQuest and Licensee.  Neither party shall have any right, power or authority
to bind the other or assume, create or incur any expense, liability or
obligation, express or implied, on behalf of the other.

     11.10. Assignment.  The parties agree that their rights and obligations
under this Agreement may not be transferred or assigned to a third party without
the prior written consent of the other party hereto. Notwithstanding the
foregoing, a party may transfer or assign its rights and obligations under this
Agreement, without consent, to a successor to all or substantially all of its
business or assets relating to this Agreement whether by sale, merger, operation
of law or otherwise. Any assignment not in conformance with this Section 12.10
shall be null, void and of no legal effect.

     11.11. Notices.  Any notice, report, communication or consent required or
permitted by this Agreement shall be in writing and shall be sent (a) by prepaid
registered or certified mail, return receipt requested, (b) by overnight express
delivery service by a nationally recognized courier, or (c) via confirmed
facsimile or telecopy, followed within five (5) days by a copy mailed in the
preceding manner, addressed to the other party at the address shown below or at
such other address for which such party gives notice hereunder.  Such notice
will be deemed to have been given when delivered or, if delivery is not
accomplished by some fault of the addressee, when tendered.

            If to AgraQuest:           AgraQuest, Inc.
                                       1530 Drew Avenue
                                       Davis, CA 95616
                                       Attn: Dr. Pamela G. Marrone
                                       Main: (530) 750-0150
                                       Facsimile: (530) 750-0153

            If to License e:           Dragoco, Inc.
                                       One Gordon Drive
                                       Totowa, New Jersey 07512
                                       Attn: Klaus Stanzl, Ph.D
                                       Facsimile: _____________

     11.12. Modification; Waiver. This Agreement may not be altered, amended or
modified in any way except by a writing signed by both parties. The failure of a
party to enforce any rights or provisions of the Agreement shall not be
construed to be a waiver of such rights or provisions, or a waiver by such
[***] Confidential information has beem omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R (S) 230.406.

                                       11
<PAGE>

party to thereafter enforce such rights or provision or any other rights or
provisions hereunder. No waiver shall be effective unless made in writing and
signed by the waiving party.

     11.13.  Severability.  If any provision of any provision of this Agreement
shall be found by a court to be void, invalid or unenforceable, the same shall
be reformed to comply with applicable law or stricken if not so conformable, so
as not to affect the validity or enforceability of this Agreement; provided that
no such reformation or striking shall be effective if the result materially
changes the economic benefit of this Agreement to either AgraQuest or Licensee.
In the event that any provision of this Agreement becomes or is declared by a
court of competent jurisdiction to be void, invalid or unenforceable, and
reformation or striking of such provision would materially change the economic
benefit of this Agreement to either AgraQuest or Licensee, AgraQuest and
Licensee shall modify such provision in accordance with this Section 11.13 to
obtain a legal, valid and enforceable provision and provide an economic benefit
to AgraQuest and Licensee that most nearly effects AgraQuest's and Licensee'
intent on entering into this Agreement.

     11.14.  Entire Agreement.  The parties hereto acknowledge that this
Agreement, together with the exhibits attached hereto, set forth the entire
agreement and understanding of the parties as to the subject matter hereto, and
supersedes all prior and contemporaneous discussions, agreements and writings in
respect hereto.

     11.15.  Headings. The article, section and paragraph headings contained
herein are for the purposes of convenience only and are not intended to define
or limit the contents of the articles, sections or paragraphs to which such
headings apply.

     11.16.  Counterparts.  This Agreement may be executed in two or more
counterparts, each of which shall be deemed an original and all of which
together shall constitute one instrument.

[***] Confidential information has beem omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R (S) 230.406.

                                       12
<PAGE>

     IN WITNESS WHEREOF, AgraQuest and Licensee have executed this Agreement by
their respective duly authorized representatives.

AgraQuest, Inc.                         DragocoGerberding & Co.AG
 ("AgraQuest")                           ("Licensee")

By:    /s/ Pam Marrone                  By:    /s/ Klaus Stanzl
       ---------------------------             --------------------------
Name:  Pam Marrone                      Name:  Klaus Stanzl
       ---------------------------             --------------------------
Title: President, CEO                   Title: Corp. Vice President
       ---------------------------             --------------------------
       8/20/01                                 Head of Cosmetics Division
       Aug. 20, 2001                           Worldwide

[***] Confidential information has beem omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R (S) 230.406.

                                       13
<PAGE>

                                   Exhibit A

                               Licensed Patents
                               ----------------

[***]
[***]
[***]
[***]
[***]

[***] Confidential information has beem omitted and filed separately with the
Securities and Exchange Commission pursuant to 17 C.F.R (S) 230.406.

                                       14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00033-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00033-of-00352.parquet"}]]